A Phase 2 Pilot Feasibility Study of Palbociclib in Combination with Adjuvant Endocrine Therapy for Hormone Receptor Positive Invasive Breast Carcinoma
K
Kathy Miller, MD
Primary Investigator
J
Jessica MacLean
Primary Investigator
Overview
The purpose of this research is to evaluate a drug called Palbociclib in combination with endocrine therapy as a possible treatment for hormone receptor positive breast cancer.
Description
This is a multi-center, single arm, phase II pilot study. It is a non-randomized, open label study of the feasibility of longer duration combination therapy with palbociclib and adjuvant endocrine therapy in patients with higher-risk HR+ breast cancer.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
breast cancer
-
Age: Between 18 Years - 100 Years
-
Gender: All
Updated on
26 Apr 2024.
Study ID: 1411719920 (13-559)
